Amgen Inc. $AMGN Stock Sold by MRA Advisory Group

MRA Advisory Group lessened its stake in Amgen Inc. (NASDAQ:AMGN) by 66.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,441 shares of the medical research company’s stock after selling 2,815 shares during the period. MRA Advisory Group’s holdings in Amgen were worth $608,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently made changes to their positions in the company. Kwmg LLC lifted its holdings in shares of Amgen by 1.0% in the 3rd quarter. Kwmg LLC now owns 22,844 shares of the medical research company’s stock valued at $9,629,000 after purchasing an additional 221 shares during the last quarter. Worth Asset Management LLC acquired a new stake in shares of Amgen in the third quarter valued at approximately $1,407,000. First Community Trust NA increased its holdings in shares of Amgen by 24.5% in the 3rd quarter. First Community Trust NA now owns 1,167 shares of the medical research company’s stock valued at $492,000 after acquiring an additional 230 shares during the period. Weaver Consulting Group grew its position in Amgen by 3.9% during the 3rd quarter. Weaver Consulting Group now owns 1,696 shares of the medical research company’s stock worth $715,000 after purchasing an additional 63 shares during the last quarter. Finally, Nautilus Advisors LLC raised its holdings in shares of Amgen by 2.3% in the third quarter. Nautilus Advisors LLC now owns 2,096 shares of the medical research company’s stock valued at $884,000 after buying an additional 48 shares during the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Insider Transactions at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 2,970 shares of the stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the sale, the senior vice president owned 7,340 shares in the company, valued at approximately $2,951,854.40. This represents a 28.81% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Rachna Khosla sold 2,000 shares of the business’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total value of $825,140.00. Following the completion of the transaction, the senior vice president directly owned 6,404 shares of the company’s stock, valued at approximately $2,642,098.28. This trade represents a 23.80% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 6,222 shares of company stock valued at $2,540,926. 0.85% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several analysts have commented on the company. Guggenheim upped their price objective on Amgen from $343.00 to $388.00 and gave the company a “neutral” rating in a research note on Monday, August 10th. Bank of America upped their price target on Amgen from $312.00 to $317.00 and gave the stock an “underperform” rating in a research note on Wednesday, August 5th. Scotiabank boosted their price objective on shares of Amgen from $450.00 to $500.00 and gave the company an “outperform” rating in a research note on Monday, September 28th. Citigroup upped their price objective on shares of Amgen from $345.00 to $405.00 and gave the stock a “neutral” rating in a research report on Friday, August 7th. Finally, Morgan Stanley lowered their target price on shares of Amgen from $362.00 to $359.00 and set an “equal weight” rating on the stock in a report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, sixteen have issued a Hold rating and three have given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $385.79.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen reported that its AMG 513 obesity-drug study completed Phase 1. The milestone provides an additional potential growth opportunity in the competitive weight-loss market, although clinical efficacy and safety data remain important next steps. Amgen AMG 513 obesity trial article
• Positive Sentiment: Scotiabank raised its price target for Amgen from $450 to $500, signaling greater confidence in the company’s upside potential and supporting sentiment around the stock. Scotiabank raises Amgen price target
• Neutral Sentiment: Truist raised its target from $362 to $380 but maintained a Hold rating. The revised target remains below the recent trading level, limiting the bullish impact of the increase.
• Neutral Sentiment: Cantor Fitzgerald reiterated a Neutral rating, while another report cited a $400 target. These views suggest analysts see limited near-term upside after Amgen’s strong run. Cantor Fitzgerald Amgen rating
• Neutral Sentiment: Amgen has become a heavily watched or “trending” stock on Zacks, which may increase trading attention but does not represent a fundamental change in the company’s outlook. Zacks Amgen trending stock article
• Negative Sentiment: Morgan Stanley lowered its target from $362 to $359 and retained an Equal Weight rating. The target implies substantial downside from current levels, reinforcing concerns that expectations and valuation may be elevated. Morgan Stanley Amgen price target report

Amgen Price Performance

Shares of AMGN stock traded up $10.81 during midday trading on Wednesday, reaching $413.42. 992,761 shares of the company traded hands, compared to its average volume of 2,752,233. The firm has a market cap of $223.51 billion, a PE ratio of 25.66, a price-to-earnings-growth ratio of 2.91 and a beta of 0.41. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.13. The firm’s 50 day simple moving average is $411.44 and its two-hundred day simple moving average is $371.01. Amgen Inc. has a 1-year low of $288.00 and a 1-year high of $447.03.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, beating the consensus estimate of $5.62 by $0.67. The firm had revenue of $10.05 billion during the quarter, compared to the consensus estimate of $9.43 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%.Amgen’s quarterly revenue was up 9.5% on a year-over-year basis. During the same period last year, the business posted $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, equities research analysts expect that Amgen Inc. will post 22.94 EPS for the current fiscal year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, September 11th. Shareholders of record on Friday, August 21st were issued a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a yield of 2.4%. The ex-dividend date was Friday, August 21st. Amgen’s dividend payout ratio (DPR) is 62.65%.

About Amgen

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research and commercial activities focus on areas including oncology, cardiovascular disease, inflammation, bone health, neuroscience and rare diseases. The company uses biologic research, human genetics and other advanced technologies to develop targeted therapies and supports patients through treatment and disease-management services.

Amgen’s portfolio includes medicines such as Enbrel for inflammatory diseases; Prolia and Evenity for osteoporosis; Xgeva for cancer-related bone complications; Repatha for certain cardiovascular conditions; Otezla for inflammatory diseases; Aimovig for migraine prevention; Tezspire for severe asthma; and Lumakras for certain cancers.